Three members of Novartis’ executive committee will leave company in 2015

9 October 2014

Swiss drug major Novartis (NOVN: VX) has announced that three members of its executive committee will leave the company.

The announcement follows the completion of transactions with UK pharma major GlaxoSmithKline (LSE: GSK) and US drug major Eli Lilly (NYSE: LLY). The expected changes to the executive committee are subject to the closing of the transactions announced on April 22. Novartis expects the transaction with GSK to be completed in the first half of 2015, and the transaction with Eli Lilly for its Animal Health Business to close in the first quarter of 2015.

George Gunn, currently division head, Novartis Animal Health, will reach his contractual retirement age in July 2015 and will retire from Novartis. On closing of the Animal Health transaction with Lilly he will leave the ECN.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK